-
Mashup Score: 5Treatment Sequence for Osteoporosis - 22 hour(s) ago
Osteoporosis is a chronic progressive disease that requires lifelong monitoring and treatment. Sequencing from one treatment to another at different ages and stages of disease is an approach that can maximize benefits and avoid potential risks from long-term treatment with a single agent.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 28
Incidental radiographic findings of an empty sella are prevalent in up to 35% of the general population. While empty sella was initially considered clinically insignificant, a subset of patients exhibits endocrine or neuro-ophthalmologic manifestations which are diagnostic of empty sella syndrome (ESS). Recent studies suggest that more patients are affected by ESS than previously recognized, necessitating a deeper understanding of this condition. This comprehensive review describes a practical approach to evaluating and managing ESS.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 6
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed for type 2 diabetes mellitus (DM) treatment, have shown potential benefits beyond glycemic control, including a positive impact on the blood pressure (BP). This meta-analysis aimed to evaluate their effects on patients with type 2 DM and hypertension.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 12
It is estimated that 43 720 new cases of thyroid cancer will be diagnosed in 2023.1 Owing to advances in diagnosis and treatment, the 5-year relative survival rate for patients is 98.5%. The number of thyroid cancer survivors has been increasing due to increasing incidence, young age at diagnosis, and generally good survival. In fact, thyroid cancer is the third most common cancer among female cancer survivors.2
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 12
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed for type 2 diabetes mellitus (DM) treatment, have shown potential benefits beyond glycemic control, including a positive impact on the blood pressure (BP). This meta-analysis aimed to evaluate their effects on patients with type 2 DM and hypertension.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 19A Comprehensive Review of Empty Sella and Empty Sella Syndrome - 10 day(s) ago
Incidental radiographic findings of an empty sella are prevalent in up to 35% of the general population. While empty sella was initially considered clinically insignificant, a subset of patients exhibits endocrine or neuro-ophthalmologic manifestations which are diagnostic of empty sella syndrome (ESS). Recent studies suggest that more patients are affected by ESS than previously recognized, necessitating a deeper understanding of this condition. This comprehensive review describes a practical approach to evaluating and managing ESS.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 8Treatment Sequence for Osteoporosis - 10 day(s) ago
Osteoporosis is a chronic progressive disease that requires lifelong monitoring and treatment. Sequencing from one treatment to another at different ages and stages of disease is an approach that can maximize benefits and avoid potential risks from long-term treatment with a single agent.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 46Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia - 18 day(s) ago
Hyperglycemia in patients with type 2 diabetes mellitus is frequently encountered in the hospital setting. The recent guidelines for the management of inpatient hyperglycemia have included the use of dipeptidyl peptidase 4 inhibitors as an alternative to standard insulin therapy in select patients. This raises the question of the inpatient use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), which have gained increasing popularity in the outpatient setting because of beneficial cardiovascular and renal outcomes.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 8Pros of Inpatient Sodium Glucose Cotransporter-2 Inhibitor Use - 19 day(s) ago
Sodium-glucose-cotransporter 2 (SGLT-2) inhibitors are widely used for diabetes management especially because their effects go beyond glucose control. More recently, their indications and usage have expanded to heart failure (HF) and renal dysfunction therapy in patients both with and without diabetes. Beneficial effects, especially for HF readmission, accrue very early in their treatment trajectory, and this has promoted their use in the hospital setting. Data on their safety and efficacy for inpatient use are accumulating but have lagged behind the outpatient data for their use.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 8Pros of Inpatient Sodium Glucose Cotransporter-2 Inhibitor Use - 22 day(s) ago
Sodium-glucose-cotransporter 2 (SGLT-2) inhibitors are widely used for diabetes management especially because their effects go beyond glucose control. More recently, their indications and usage have expanded to heart failure (HF) and renal dysfunction therapy in patients both with and without diabetes. Beneficial effects, especially for HF readmission, accrue very early in their treatment trajectory, and this has promoted their use in the hospital setting. Data on their safety and efficacy for inpatient use are accumulating but have lagged behind the outpatient data for their use.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
Awareness of the importance of treatment sequence can help improve osteoporosis care across the postmenopausal lifespan. Read more: https://t.co/87FoMbKS0S #endotwitter @vtangpricha @Els_ENDO